Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Leukemia ; 30(10): 2019-2025, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27133817

RESUMEN

This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the GCLLSG evaluating fludarabine (F) vs F+cyclophosphamide (FC), chlorambucil vs F, FC without or with rituximab, and bendamustine+R (BR). Among 1458 patients, 239 (16.4%) experienced either an SPM (N=191) or a RT (N=75). Solid tumors (N=115; 43.2% of all second neoplasias) appeared most frequently, followed by RTs (N=75; 28.2%). Patients showed a 1.23-fold increased risk of solid tumors in comparison to the age-matched general population from the German cancer registry. Age>65 (hazard ratio (HR) 2.1; P<0.001), male sex (HR 1.7; P=0.01), co-morbidities (HR 1.6; P=0.01) and number of subsequent treatments⩾1 (HR 12.1; P<0.001) showed an independent adverse prognostic impact on SPM-free survival. Serum thymidine kinase>10 U/l at trial enrollment (HR 3.9; P=0.02), non-response to first-line treatment (HR 3.6; P<0.001) and number of subsequent treatments⩾1 (HR 30.2; P<0.001) were independently associated with increased risk for RT.


Asunto(s)
Transformación Celular Neoplásica/inducido químicamente , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Neoplasias Primarias Secundarias/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Clorhidrato de Bendamustina/administración & dosificación , Clorhidrato de Bendamustina/uso terapéutico , Estudios de Casos y Controles , Clorambucilo/administración & dosificación , Clorambucilo/uso terapéutico , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Alemania , Humanos , Leucemia Linfocítica Crónica de Células B/mortalidad , Masculino , Persona de Mediana Edad , Neoplasias Primarias Secundarias/mortalidad , Sistema de Registros , Medición de Riesgo , Factores de Riesgo , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados , Vidarabina/uso terapéutico
3.
Ann Hematol ; 94(10): 1717-25, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26259502

RESUMEN

Allogeneic stem cell transplantation is a treatment option for patients with poor risk CLL. We conducted a retrospective analysis of all CLL patients allografted at our institution, the University Hospital of Cologne, Germany. Data was collected on 40 patients from 2004 to 2012. The mean age was 54, and the majority were male (75 %). On average, the patients were diagnosed 6 years (range 2-12) prior to transplant with an average of 4 years (range 1-8) from time of first-line therapy to transplant. The remission states at the time of transplant were complete remission (CR) (n = 4), stable disease (n = 10), partial remission (n = 20) and progressive disease (n = 6). Only reduced intensity conditioning regimens were employed. The average CD34(+) cell dose was 4.16 × 10(6)/kg. Neutrophil engraftment was seen by day +17 (range 10-23) post-transplant, and 88 % achieved 95-100 % donor chimerism by day 100. Overall survival, progression-free survival and non-relapse mortality at 2 years post-transplant were 65, 52.5 and 27.5 %, respectively. A total of 51 % of patients were found to be minimal residual disease (MRD)-negative at 1 year post-transplant. Our single-centre experience confirms the valuable role of allogeneic stem cell transplantation (allo-SCT) in the treatment of poor risk CLL patients with promising long-term survival and acceptable transplant-related mortality. The advent of newer therapeutic agents should not hinder the consideration of allo-SCT for this patient cohort as it remains the only curative option for these patients.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/mortalidad , Leucemia Linfocítica Crónica de Células B/mortalidad , Leucemia Linfocítica Crónica de Células B/terapia , Adulto , Anciano , Femenino , Trasplante de Células Madre Hematopoyéticas/tendencias , Humanos , Leucemia Linfocítica Crónica de Células B/diagnóstico , Masculino , Persona de Mediana Edad , Morbilidad , Mortalidad/tendencias , Estudios Retrospectivos , Trasplante Homólogo/mortalidad , Trasplante Homólogo/tendencias , Resultado del Tratamiento
4.
Dtsch Med Wochenschr ; 138(13): 655-7, 2013 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-23512367

RESUMEN

Morbidity and mortality (M&M) conferences serve as a forum for the discussion of adverse events and errors in the treatment of patients. In the United States M&M conferences are an established part of medical training programs. While being state of the art in specialities like surgery and anesthesiology, they were established later on in internal medicine. To date, no reports have been published on M&M conferences in departments of internal medicine in Germany. Since August 2010 a morbidity and mortality conference takes place once per month in the Department I of Internal Medicine of the university hospital of Cologne. Cases with unexpected death, unexpected complications or medical errors are discussed. The primary goal is to create an open and confidential forum for doctors, where errors can be discussed without any assignment of guilt. The uncovering of structural problems frequently leads to direct improvements in patient care. Furthermore, the conference can play an important role in medical education.


Asunto(s)
Congresos como Asunto , Educación Médica Continua , Educación de Postgrado en Medicina , Mortalidad Hospitalaria , Medicina Interna/educación , Medicina Interna/normas , Errores Médicos , Morbilidad , Alemania , Humanos , Control de Calidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA